Journal article icon

Journal article

A multicenter, randomized, placebo‐controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis

Abstract:

OBJECTIVE:Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVE in RA patients. METHODS:Randomized, double-blind, placebo-controlled trial designed for 80% power at p<0.05 to detect a 32% CVE risk reduction based on an estimated 1.8% per annum (pa) event rate. Patients aged >50 years or with RA duration >10 years; ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/art.40892

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author

Contributors

Role:
Contributor
Publisher:
Wiley Periodicals
Journal:
Arthritis and Rheumatology More from this journal
Volume:
71
Issue:
9
Pages:
1437-1449
Publication date:
2019-04-15
Acceptance date:
2019-02-19
DOI:
EISSN:
2326-5205
ISSN:
2326-5191
Pmid:
30983166
Language:
English
Keywords:
Pubs id:
pubs:993231
UUID:
uuid:8c581126-1716-40d1-a1b6-175f35f046cc
Local pid:
pubs:993231
Source identifiers:
993231
Deposit date:
2019-05-31

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP